Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib plus Etoposide in Advanced Hormone Refractory Prostate Cancer
NCT00483561Phase 2Terminated
- Sponsor
- University of Nebraska
- Start
- Jan 2004
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in prostate cancer (PCa), sponsored by University of Nebraska. Primary endpoint: Overall Response Rate at 3 years. Started Jan 2004; status: terminated.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00483561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00483561.